Physician profile
Sakina Bajowala
NPI 1427259605
$72,402.95
in general payments reported to CMS, 2019-2025
17 companies · $66K in 2025
The $66K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $26.52 · 2021: $1,449 · 2022: $477 · 2023: $3,540 · 2024: $321 · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $8,402 · Consulting Fee: $2,731 · Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,700.00 |
| Travel and Lodging | $8,402.21 |
| Consulting Fee | $2,731.25 |
| Food and Beverage | $2,451.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $66,156.46 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $4,748.23 | 2019-2023 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $471.91 | 2019-2024 | Fasenra |
| Genzyme Corporation | $186.29 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $157.86 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $139.25 | 2024-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $123.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $94.66 | 2022 | |
| Alk-Abello, INC | $75.07 | 2021-2022 | |
| Kaleo, INC. | $54.01 | 2019-2020 | |
| Genentech USA, INC. | $41.25 | 2025 | Xolair |
| Shire North American Group INC | $40.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.72 | 2021 | |
| Genentech, INC. | $30.01 | 2023 | Xolair |
| Glaxosmithkline, LLC. | $16.69 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.65 | 2023 | Rinvoq |
| Pharming Healthcare, INC. | $13.82 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakina Bajowala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.